Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Bristol acquires heart failure company Cardioxyl for up to $2.1bn

09 Sep 2020

Executive Summary

Bristol-Myers Squibb Co. spent $300mm in up-front and near-term milestone payments for Cardioxyl Pharmaceuticals Inc., a private heart failure drug developer. Cardioxyl is also eligible for up to $1.775bn in development, regulatory, and sales milestones.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By